Because of insufficient targeting to BCSCs, trastuzumab treatment finally fails.43, 44 Therefore, treatment for HER2‐overexpressing breast cancer should target the BCSC population along with the remaining tumour cells. Here, ERBB2 is linked to breast cancer.